Thanks for the quick math. Hopefully they have a plan to speed the enrollment up here in the U.S. I figure enrollment is slow as COVID cases have decreased while competitor trials have increased. I don’t doubt it’s hard for a small biotech to compete with the BP’s with deep pockets. The U.K. sites need to start enrolling as well but I know their cases are far fewer than the U.S.